237 related articles for article (PubMed ID: 11862109)
1. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.
Shimokawa H
J Cardiovasc Pharmacol; 2002 Mar; 39(3):319-27. PubMed ID: 11862109
[TBL] [Abstract][Full Text] [Related]
2. [Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
Nakayama M; Amano M; Kawabata S; Kaibuchi K; Takefuji M
Nihon Rinsho; 2004 Mar; 62 Suppl 3():202-6. PubMed ID: 15171369
[No Abstract] [Full Text] [Related]
3. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo.
Shimokawa H; Morishige K; Miyata K; Kandabashi T; Eto Y; Ikegaki I; Asano T; Kaibuchi K; Takeshita A
Cardiovasc Res; 2001 Jul; 51(1):169-77. PubMed ID: 11399259
[TBL] [Abstract][Full Text] [Related]
4. Progress of the study of rho-kinase and future perspective of the inhibitor.
Tawara S; Shimokawa H
Yakugaku Zasshi; 2007 Mar; 127(3):501-14. PubMed ID: 17329936
[TBL] [Abstract][Full Text] [Related]
5. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.
Masumoto A; Mohri M; Shimokawa H; Urakami L; Usui M; Takeshita A
Circulation; 2002 Apr; 105(13):1545-7. PubMed ID: 11927519
[TBL] [Abstract][Full Text] [Related]
6. Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm.
Kandabashi T; Shimokawa H; Miyata K; Kunihiro I; Eto Y; Morishige K; Matsumoto Y; Obara K; Nakayama K; Takahashi S; Takeshita A
Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2209-14. PubMed ID: 14592852
[TBL] [Abstract][Full Text] [Related]
7. Rho-kinase is an important therapeutic target in cardiovascular medicine.
Shimokawa H; Takeshita A
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1767-75. PubMed ID: 16002741
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the study of Rho kinase and its inhibitors].
Duan WG; Yuan ST; Liao H; Yan M; Zhang LY
Yao Xue Xue Bao; 2007 Oct; 42(10):1013-22. PubMed ID: 18229604
[TBL] [Abstract][Full Text] [Related]
10. Rho/Rho kinase as a potential target for the treatment of renal disease.
Wakino S; Kanda T; Hayashi K
Drug News Perspect; 2005 Dec; 18(10):639-43. PubMed ID: 16491166
[TBL] [Abstract][Full Text] [Related]
11. Microtubule disruption modulates the Rho-kinase pathway in vascular smooth muscle.
Zhang D; Wang Z; Jin N; Li L; Rhoades RA; Yancey KW; Swartz DR
J Muscle Res Cell Motil; 2001; 22(2):193-200. PubMed ID: 11519742
[TBL] [Abstract][Full Text] [Related]
12. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system.
Higashi M; Shimokawa H; Hattori T; Hiroki J; Mukai Y; Morikawa K; Ichiki T; Takahashi S; Takeshita A
Circ Res; 2003 Oct; 93(8):767-75. PubMed ID: 14500337
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
Fukumoto Y; Tawara S; Shimokawa H
Tohoku J Exp Med; 2007 Apr; 211(4):309-20. PubMed ID: 17409670
[TBL] [Abstract][Full Text] [Related]
14. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries.
Kandabashi T; Shimokawa H; Mukai Y; Matoba T; Kunihiro I; Morikawa K; Ito M; Takahashi S; Kaibuchi K; Takeshita A
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):243-8. PubMed ID: 11834523
[TBL] [Abstract][Full Text] [Related]
15. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
Otsuka T; Ibuki C; Suzuki T; Ishii K; Kodani E; Atarashi H; Kishida H; Takano T
Circ J; 2006 Apr; 70(4):402-8. PubMed ID: 16565555
[TBL] [Abstract][Full Text] [Related]
16. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
Mohri M; Shimokawa H; Hirakawa Y; Masumoto A; Takeshita A
J Am Coll Cardiol; 2003 Jan; 41(1):15-9. PubMed ID: 12570938
[TBL] [Abstract][Full Text] [Related]
17. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.
Sasaki Y; Suzuki M; Hidaka H
Pharmacol Ther; 2002; 93(2-3):225-32. PubMed ID: 12191614
[TBL] [Abstract][Full Text] [Related]
18. Rho-kinase and myosin II activities are required for cell type and environment specific migration.
Nakayama M; Amano M; Katsumi A; Kaneko T; Kawabata S; Takefuji M; Kaibuchi K
Genes Cells; 2005 Feb; 10(2):107-17. PubMed ID: 15676022
[TBL] [Abstract][Full Text] [Related]
19. [Involvement of Rho-kinase in hypertensive vascular disease--a novel therapeutic target in hypertension].
Mukai Y
Fukuoka Igaku Zasshi; 2002 Aug; 93(8):129-34. PubMed ID: 12382411
[No Abstract] [Full Text] [Related]
20. Rho kinase as a therapeutic target in cardiovascular disease.
Surma M; Wei L; Shi J
Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
